“Dr. was very thorough in explaining my glaucoma condition and treatments. Much more than 2 ophthalmologists I saw in NY for 8 years. He's a 10-star doctor!”
Lucentis (Ranibizumab) for Retinal Disease: What Patients Should Know
Conditions Lucentis Is Approved to Treat
Lucentis is FDA-approved for five retinal conditions, all of which involve VEGF-driven damage to the eye. Your retina specialist will determine which treatment approach is most appropriate based on your specific diagnosis and imaging findings.
Wet AMD occurs when abnormal blood vessels grow beneath the macula and leak fluid or blood. It is the most common reason patients receive Lucentis injections. Without treatment, wet AMD can cause rapid and severe central vision loss. Ranibizumab was originally developed and approved specifically for this condition, and its long-term safety record in wet AMD is well established.
Diabetic macular edema (DME) is swelling in the macula caused by fluid leaking from damaged blood vessels in patients with diabetes. Diabetic retinopathy (DR) refers more broadly to retinal damage from diabetes, including abnormal vessel growth across the retina. Lucentis is FDA-approved for both conditions. Reducing VEGF levels helps dry up the swelling and can slow the progression of vessel damage in diabetic eyes.
A retinal vein occlusion (RVO) occurs when a vein in the retina becomes blocked, causing fluid to back up and leak into the macula. This results in swelling and blurred central vision. Lucentis helps by reducing the VEGF response that follows the blockage, clearing fluid and protecting macular tissue from further damage.
In people with high myopia (severe nearsightedness), abnormal blood vessels can grow beneath the retina in a process called choroidal neovascularization (CNV). Lucentis is approved to treat this condition and can help stop the growth of these vessels before they cause lasting damage to central vision.
What the Injection Experience Is Like
Many patients feel anxious before their first intravitreal injection. Understanding each step of the process can help reduce that concern. The procedure is brief, performed in our clinic, and most patients tolerate it well.
Before the injection, your retina specialist numbs your eye with anesthetic drops so you will not feel the needle. An antiseptic solution is applied to the surface of the eye to reduce the risk of infection. A small eyelid holder may be used to keep your eye open during the procedure. The preparation takes only a few minutes.
The injection itself takes just a few seconds. Your retina specialist uses a very thin needle to deliver the medication through the white part of the eye (the sclera) into the vitreous, the clear gel-filled space inside the eye. Most patients describe a sensation of mild pressure rather than sharp pain. The full appointment, including preparation and a brief observation period, typically takes 30 minutes to one hour.
It is normal to notice mild redness at the injection site, a gritty or sandy feeling, or slightly blurred vision for a few hours after the procedure. These effects usually clear up within a day. Your specialist may check your eye pressure before you leave the office.
- Arrange for a driver to take you home after your appointment
- Avoid rubbing your eye for the remainder of the day
- Stay away from swimming pools and dusty environments for a few days
- Use preservative-free artificial tears if your eye feels dry or irritated
Most patients return to their normal activities within hours of the injection.
Treatment Schedule and Ongoing Monitoring
How often you receive Lucentis injections depends on your condition, how your retina responds, and the approach your retina specialist recommends. Consistent follow-up is one of the most important factors in protecting your vision long-term.
Lucentis was originally studied and approved as a monthly injection. For wet AMD, diabetic macular edema, and retinal vein occlusion, a series of monthly injections is the typical starting approach. This consistent loading phase establishes control over fluid and abnormal vessel activity and forms the foundation on which further treatment decisions are made.
After the initial series of monthly injections, many retina specialists use a treat-and-extend approach. In this strategy, the interval between injections is gradually increased based on how your retina is responding. At each visit, imaging tests such as optical coherence tomography (OCT, a non-invasive scan that produces detailed cross-section images of the retina) are used to check for fluid or swelling.
- If the retina remains dry and stable, the interval between injections may be extended
- If fluid returns, the interval is shortened to regain control
- The goal is to find the longest safe interval that keeps your retina stable
This individualized approach reduces the overall number of injections while maintaining the benefits of treatment.
Long-term follow-up data shows that patients who maintain their treatment schedule tend to have better outcomes over time. When injections are skipped or delayed, fluid can return to the retina and vision gains may be lost. Even when your vision feels stable, continued monitoring allows your specialist to detect any changes early and adjust treatment before significant damage occurs. If you need to reschedule an appointment, contact our office as soon as possible.
Benefits and Risks of Lucentis Treatment
Like any medical procedure, intravitreal injections carry both potential benefits and risks. Your retina specialist will review these with you and help you weigh them in the context of your specific condition.
Lucentis was the first anti-VEGF medication shown to improve vision in patients with wet AMD, a significant milestone in retinal care. In the landmark MARINA clinical trial, patients receiving ranibizumab gained an average of 6 to 7 letters of visual acuity over 12 months, while untreated patients lost an average of more than 10 letters. Many patients in clinical trials experienced gains meaningful enough to resume activities such as reading and recognizing faces. For most patients, the primary goal is to stabilize vision and prevent further loss, with improvement as a possible additional outcome.
The most frequently reported side effects are mild and temporary. These include redness at the injection site, a gritty or foreign-body sensation, minor eye discomfort, and brief blurred vision. Floaters (small spots or shadows in your vision caused by the injection) may be noticeable for a day or two. These effects are typical of intravitreal injections and generally resolve on their own.
Serious complications from intravitreal injections are uncommon but possible. They include eye infection (endophthalmitis, an infection inside the eye), retinal detachment, elevated eye pressure, and bleeding inside the eye. The risk of endophthalmitis per injection is low, and antiseptic preparation before each injection is used specifically to minimize that risk. Seek immediate care if you experience sudden vision loss, severe or worsening eye pain, or markedly increased redness or swelling after an injection.
How Lucentis Compares to Other Anti-VEGF Options
Ranibizumab is one of several anti-VEGF medications available for retinal disease. Your retina specialist will consider your diagnosis, treatment history, and individual response when selecting the most appropriate option.
Several anti-VEGF medications are currently in use for retinal conditions. Eylea (aflibercept) and Vabysmo (faricimab) are both FDA-approved for wet AMD and DME and may offer extended dosing intervals for some patients. Vabysmo works by targeting both VEGF and a second protein called angiopoietin-2, which plays a role in blood vessel stability. Avastin (bevacizumab) is used off-label for retinal conditions and is often selected because of its lower cost. Each medication has its own clinical profile, dosing schedule, and patient population where it may be preferred.
FDA-approved biosimilar versions of ranibizumab are now available. A biosimilar is a medication that contains the same active ingredient as the original product and has been shown to be highly similar in safety and effectiveness. Real-world evidence from thousands of injections has shown that approved ranibizumab biosimilars produce outcomes consistent with the original medication. Biosimilars may provide an additional option for patients who respond well to ranibizumab. Your retina specialist can discuss whether a biosimilar is appropriate for your treatment plan.
No single anti-VEGF medication is the best choice for every patient. Factors such as the specific condition being treated, how your retina has responded to previous treatment, your overall health, and practical considerations like appointment frequency all play a role in treatment selection. Our team evaluates each patient individually using retinal imaging and clinical findings to recommend the approach most likely to protect your vision.
Recognizing When to Seek Urgent Care
Knowing which symptoms require immediate attention can protect your vision. Some changes should not wait for your next scheduled appointment.
Most discomfort after an injection is mild and short-lived. However, certain symptoms may indicate a serious complication and require prompt evaluation. Contact your retina specialist immediately or go to the nearest emergency room if you experience any of the following after an injection:
- Sudden or significant loss of vision
- Severe or rapidly worsening eye pain
- Marked increase in redness, swelling, or discharge
- A large new floater or curtain-like shadow across your vision
These symptoms could indicate endophthalmitis or another serious complication that requires same-day treatment.
Even between scheduled visits, certain vision changes should prompt urgent attention. A sudden increase in floaters, new flashes of light, a shadow or dark curtain spreading across part of your vision, or sudden blurring in one eye are all warning signs of a possible retinal tear or detachment. These conditions require immediate evaluation, regardless of when your next appointment is scheduled. Do not wait and see if these symptoms improve on their own.
Frequently Asked Questions
Below are answers to questions our patients commonly ask about Lucentis treatment, including practical guidance for navigating your care.
The choice of anti-VEGF medication depends on your specific diagnosis, the characteristics of your retinal disease seen on imaging, any prior treatment history, and your retina specialist's clinical judgment. Some patients do equally well on multiple agents, while others show a better response to one particular medication. Your specialist will use OCT imaging and other diagnostic tools at each visit to assess your response and may recommend switching medications if your current treatment is not achieving adequate control of fluid or abnormal vessel activity.
Ranibizumab can improve vision in many patients, particularly when treatment is started early before significant retinal damage has occurred. Clinical trial data showed meaningful visual gains in a substantial percentage of patients. However, vision that has been lost due to long-standing or severe retinal damage, such as scarring beneath the macula, may not be fully recoverable. The primary goal of treatment is to stabilize your current vision and prevent further decline, with improvement as a meaningful but not guaranteed additional outcome.
Gaps in treatment can allow VEGF levels to rise again, which may cause fluid to return to the retina and lead to vision decline. If you need to miss or reschedule an appointment, contact our office as soon as possible so we can get you back on schedule with minimal delay. In most cases, treatment can be resumed and control regained, but prolonged gaps increase the risk of losing some of the vision gains achieved earlier in your treatment.
Plan to have someone drive you home after your appointment, as your vision may be temporarily blurry from the numbing drops and the injection itself. Avoid wearing eye makeup or using contact lenses on the day of the procedure. Do not rub your eye or expose it to swimming pools, hot tubs, or dusty or dirty environments for several days after the injection. If your eye feels dry or irritated afterward, preservative-free artificial tears can provide relief.
Most retinal conditions treated with anti-VEGF therapy require ongoing treatment over months to years. The duration depends on how your condition responds and whether the underlying disease process remains active. Some patients eventually reach a stable interval where injections are spread further apart, while others require more frequent treatment to maintain control. Long-term follow-up data shows that stopping treatment prematurely can lead to a return of fluid and vision loss, which is why continued monitoring is so important even during stable periods.
For some patients, ranibizumab is used as part of a broader treatment plan. For example, retinal laser photocoagulation (a targeted laser treatment applied to the retina) may be used alongside anti-VEGF injections for diabetic retinopathy or certain types of macular edema. Photodynamic therapy, a light-activated treatment, has also been used in combination with anti-VEGF therapy in select cases. Your retina specialist will determine whether any combination approach is appropriate for your individual situation.
Visit Atlantic Retina Center for Expert Retinal Care
Atlantic Retina Center is a single-specialty vitreoretinal practice dedicated exclusively to the care of the retina, vitreous, and macula across the Delmarva peninsula. Our team of fellowship-trained, board-certified retina specialists uses advanced imaging at every visit to track your retinal health over time and guide the most effective treatment plan for your individual needs. If you have been diagnosed with wet AMD, diabetic macular edema, retinal vein occlusion, or another retinal condition, we encourage you to schedule a consultation so we can evaluate your options and help protect your vision.